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ABSTRACT
To determine early somatic changes in high-grade
serous ovarian cancer (HGSOC), we performed whole
genome sequencing on a rare collection of 16
low stage HGSOCs. The majority showed extensive
structural alterations (one had an ultramutated pro-
file), exhibited high levels of p53 immunoreactivity,
and harboured a TP53 mutation, deletion or inactiva-
tion. BRCA1 and BRCA2 mutations were observed in
two tumors, with nine showing evidence of a homol-
ogous recombination (HR) defect. Combined Analy-
sis with The Cancer Genome Atlas (TCGA) indicated
that low and late stage HGSOCs have similar muta-
tion and copy number profiles. We also found evi-
dence that deleterious TP53 mutations are the earli-
est events, followed by deletions or loss of heterozy-
gosity (LOH) of chromosomes carrying TP53, BRCA1
or BRCA2. Inactivation of HR appears to be an early
event, as 62.5% of tumours showed a LOH pattern
suggestive of HR defects. Three tumours with the
highest ploidy had little genome-wide LOH, yet one of
these had a homozygous somatic frame-shift BRCA2
mutation, suggesting that some carcinomas begin as
tetraploid then descend into diploidy accompanied
by genome-wide LOH. Lastly, we found evidence that
structural variants (SV) cluster in HGSOC, but are
absent in one ultramutated tumor, providing insights
into the pathogenesis of low stage HGSOC.
INTRODUCTION
Worldwide, ovarian cancer has been estimated to affect 225
500 women and claim 140 200 lives annually (1). Themajor-
ity of ovarian cancers are of epithelial origin and consist of
four major morphological subtypes: serous, endometrioid,
clear cell and mucinous (2). Low-grade serous and muci-
nous carcinomasmay develop in stepwise fashion from ade-
nomas to carcinomas, while clear cell and endometrioid car-
*To whom correspondence should be addressed. Tel: +1 507 284 2511; Fax: +1 507 266 2478; Email: Sicotte.Hugues@mayo.edu
Correspondence may also be addressed to Lynn C. Hartmann.Tel: +1 507 266 1108; Fax: +1 507 284 1803; Email: hartmann.lynn@mayo.edu
Correspondence may also be addressed to Viji Shridhar. Tel: +1 507 266 2775; Fax: +1 507 284 1678; Email: shridhar.vijayalakshmi@mayo.edu
†These authors contributed equally to the paper as first authors.
C© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/43/14/6945/1098667 by W
ashington U
niversity in St. Louis user on 28 O
ctober 2019
6946 Nucleic Acids Research, 2015, Vol. 43, No. 14
cinomas often arise from endometriosis. In contrast, high-
grade serous (HGS) carcinomas develop from an undefined
precursor lesion and may progress rapidly without obvious
intermediate steps (3). Due to this rapid progression, as well
as the lack of specific symptoms and effective early detec-
tion methods, HGS ovarian carcinomas are the most lethal
subtype, being primarily diagnosed at advanced stages (4).
Consequently, early stage HGS ovarian carcinoma is rare
(5). In order to elucidate early events in this lethal disease,
determine whether the pathogenesis of early stage disease is
the same or different from more advanced disease, and ac-
celerate the development of genome-based biomarkers for
early detection, we analyzed whole cancer genomes for 16
low stage HGS ovarian carcinomas from the Mayo Clinic
and cancer exomes from 28 low stage and 316 late stage
HGS carcinomas from TCGA.
MATERIALS AND METHODS
Mayo Clinic patients and sequencing
We characterized the whole genomes and transcriptomes
from 16 low stage HGS ovarian cancer cases seen at Mayo
Clinic (Supplementary Tables S1 and S13). Fresh frozen
carcinomas and patient-matched blood samples were used
to generate DNA paired end libraries that were sequenced
using 100 bp reads on an Illumina GAIIx platform and
for genotyping on Illumina Human660W-Quad BeadChip
arrays. RNA sequencing was performed on 14 samples
using RNA from fresh frozen cancer tissue on the Illu-
mina GAIIx using 50 bp paired end reads. Formalin-fixed
paraffin-embedded carcinomas were used for immunohis-
tochemical staining.
TCGA data
In additional somatic mutation analyses, we utilized exome
sequence data from 28 low stage HGS carcinomas and 316
late stage HGS carcinomas from the TCGA (6). For addi-
tional copy number (CN) analysis, we utilized 28 low stage
HGS carcinomas and 446 late stage HGS carcinomas with
access-level 3 segmented data from Affymetrix 6.0 single
nucleotide polymorphism (SNP) arrays (downloaded from
tcga-data.nci.nih.gov).
Bioinformatic sequence analysis
To call DNA sequence variants using single samples, geno-
types were initially called on carcinoma and germline
samples separately using the Casava 1.7 pipeline. Those
calls were compared to the genotype calls from Illumina
Human660W-Quad BeadChip. For somatic paired variant
calling, reads were aligned with the bwa (7) aligner, then
realigned as paired samples using the IndelRealigner in
GATK v0.6 (8). Somatic variants were called with Somatic-
Sniper (SS) v1.0 (9) for single nucleotide variant (SNV) calls
and GATK Somatic Indel detector in GATK v0.6 (8) for
insertions/deletions (indels). Variants were annotated using
the TREATworkflow (10). Variants were filtered, requiring
a minimum somatic score of 15 for SNV, not overlapping
a SNP/indel in dbSNP132 (with a minor allele frequency
(MAF) of 1% or more), at least two mutant alleles in the
carcinoma (with quality of at least Q20), with one forward
and one reverse read, maximum fisher strand bias of 40, no
more than one mutant read in the germline (or 1% of cover-
age, whichever is higher) and with no more than two highly
homologous regions in the human genome (85% homology
using blat) for a region with 50 nucleotides on either side of
the variant. To identify significant somatic mutations (i.e.
enriched beyond regional background mutation rates), we
used the backgroundmutation rate computed with bmr and
smg tools of GenomeMuSiC package v0.4 (11). To count
transcript levels in RNA sequence data, 50 bp paired end
reads were aligned with against hg19 using Tophat 1.4 (12),
with the option to align first to known genes with bowtie 1;
counts were produced using htseq 0.5.3 (13).
Technical validation of Mayo Clinic somatic mutations
Five carcinomas were sequenced on a standardized
NextGen sequencing cancer panel (Supplementary Table
S2) at key genes of interest; all carcinomas with TP53
and BRCA2 mutations were confirmed by this approach.
Candidate somatic or deleterious germline mutations were
filtered from the standardized NextGen panel results by
removing common SNPs (MAF 2% of higher in dbSNP
137) as long as they did not have known deleterious alleles
in dbSNP or a locus-specific database (14). Remaining
variants are reported in Supplementary Table S3. All the
somatic variants reported by NextGen sequencing were
also included in the filtered set of somatic variants from the
whole genome sequencing.
Mutation validation with Sanger sequencing
Sanger sequencing of regions containing somatic mutations
in the 20 most frequently mutated genes among 16 tu-
mors was performed using dye termination chemistry (Big
Dye Terminator with the model 3730xl sequencer; Applied
Biosystems, CA). Primer sets for polymerase chain reac-
tion (PCR) were designed using the design tool Oligo 6.0.
PCR was carried out using AmpliTaq Gold DNA Poly-
merase (Applied Biosystems) based on the standard proto-
col. Amplicons from target genes in 16 tumors were ampli-
fied (Supplementary Table S4). After PCR, amplicons were
treated with the ExoSAP-IT (USB Corp, OH) to degrade
unincorporated PCR primers and deoxynucleotide triphos-
phates. The cleaned products were mixed with 5 pmol of
the forward or reverse PCR primers for sequencing. DNA
sequence variants were identified using Mutation Surveyor
software.
Mutation validation with RNA sequencing and qRT-PCR
data
Fourteen out of the 16 Mayo Clinic cancer samples were
also subjected to RNA-sequencing analysis as a secondary
confirmation of somatic variant calls. TopHat 1.4 was used
for alignment to human reference genome (hg19) and vari-
ant reporting was done using GATK at the locations of
DNA mutations. Additionally, for TP53, manual review
of the variants was performed using Integrative Genomics
Viewer (IGV). Validation provided by RNAwas used to es-
timate sensitivity and specificity of the DNA somatic calls.
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Quantitative Reverse Transcriptase PCR (qRT-PCR) was
also used to validate mutations.
Sensitivity and specificity of somatic variant calling pipeline
Because the variants that were Sanger sequenced were
generated by an independent pipeline, we estimated the
sensitivity/specificity of our calling strategy. Estimating the
truth for variants using Sanger sequencing results will be
a pessimistic evaluation because Sanger sequencing is not
sensitive for heterozygous mutations in tumor with low tu-
mor content or with low percentage subclones. A number of
mutations have convincing ‘high confidence NextGen’ vari-
ants (mapping quality 30, base quality 30, no overlap with
repeats, genome duplications or homologous regions) with
negative results in Sanger sequencing but mean mutant al-
lele frequency (MMAF) of only 31%, perhaps because they
were in subclones. Half of those high-confidence variants
had confirmatory RNASeq alleles, indicating that perhaps
they are below the percentage detection threshold of Sanger
sequencing. Depending on how the true positive mutations
are defined, our sensitivity/specificity can be estimated as
76%/36% (strictly trusting Sanger Results), 84%/55% (high
confidence next gen +RNASeq) and 94%/100% (or trust-
ing NextGen results over negatives in Sanger Sequencing).
Only three variants (6%) that ended up validating were
filtered out by our filtering strategy. The number of in-
dels that were Sanger sequenced was too small to evalu-
ate sensitivity/specificity, but the sensitivity should be poor
with standard GATK parameters (requires the indel be
present in at least 30% of reads).
p53 immunohistochemistry
Sections of Mayo Clinic tissues were deparaffinized, rehy-
drated and submitted to antigen retrieval by a steamer for
25 min in target retrieval solution (Dako, Carpinteria, CA,
USA). Endogenous peroxide was diminished with 3%H2O2
for 30 min. Slides were blocked in protein block solution
for 30 min and then blocked with avidin and biotin for 10
min each, followed by overnight incubation with 1:50 di-
luted anti-p53 antibody (M7001, Clone DO-7, DAKO) at
4◦C. Sections were then incubated with biotinylated univer-
sal link for 15 min and streptavidin-horseradish peroxidase
for 25 min at 25◦C. Slides were developed in diaminoben-
zidine and counterstained with hematoxylin as previously
described (15).
Copy number estimation
The CN in cancer genomes from the Mayo Clinic patients
was estimated using two approaches. First, whole genome
CN was computed using a novel algorithm (patternCNV)
which is able to use depth of coverage to compute CN varia-
tion despite local coverage variation by learning the pattern
of this coverage bias (16). PatternCNV firstly summarizes
coverage variation acrossmultiple germline samples to eval-
uate the local coverage and the variation. Somatic CN were
computed for each sample as the difference from the refer-
ence pattern in windows of 5000 nucleotides. Regions of CN
were computed using the DNAcopy package by weighting
each bin inversely to the variance of the pattern. Second, Il-
lumina 650 genotyping array data were used. We used the
paired option in Illumina GenomeStudio and extracted the
log relative ratio (LRR) and the B-allele frequency of the
germline and tumor DNA. The genoCN (17) R package
was used to detect somaticCNalterations (CNAs) requiring
a minimum of 20 probes per CNA interval. The genoCNA
function also estimates computationally the tumor purity,
defined as the percentage of cancer cells in the tissue spec-
imen (Supplementary Table S5), based on the levels of the
CN segments.
Ploidy and LOH estimation
The WaveCNV (18) segmenter was used to compute loss
of heterozygosity (LOH) and ploidy genome wide using the
pattern of alleles and CN. As input to the tool, we provided
(i) AVariant Calling Format (VCF) file containing the num-
ber of reads carrying alleles for germline variants that were
called using GATK 2.6 in discovery mode for paired sam-
ples, (ii) CN segments obtained from PatternCNV and (iii)
known tumor purity from cellularity measurements. The
program outputs ploidy, CN per segment and LOH region
calls.
CN comparisons
To minimize false detection of CNAs, we limited analysis
to recurrent regions identified in TCGA carcinomas which
were previously reported to be recurrent (19,20). The aim
was to find CN regions differing in prevalence between low
stage and high stage cases. In the first step, we used data sets
consisting of SNP-based CN estimation (15 Mayo Clinic
low stage cases excluding a detected ultramutated carci-
noma; 28 TCGA low stage cases; 446 TCGA late stage
cases) and WGS-based CN estimation (15 Mayo Clinic low
stage cases excluding a detected ultramutated carcinoma).
Given the kth region and a CN cutoff, we compute CN
occurrence frequency fk, late in late stage, and check if fk,
TCGA-early, fk, Mayo-early-SNP and fk, Mayo-early-SNP have consis-
tent and significant differencewith fk, late, based on binomial
test. Array comparative genomic hybridization (aCGH)
data from TCGA serous was downloaded as level 3 data.
Segmented data log2 ratios were then averaged over CN re-
gion of interest. Average log2 ratios were compared between
the low versus late stage carcinomas using a t-test.
Temporal relationship between somatic mutation and CN in
Mayo Clinic patients
For every gene with recurrent somatic mutations (more
than one mutation observed in Mayo Clinic low stage HGS
cases), we identified somatic SNVs (deleterious or benign)
within 1Mb of each gene. These somatic SNVs were filtered
to have at least 15 reads in the tumor (so we can accurately
estimate the frequency ofmutations), nomutant allele in the
germline, not overlapping a dbSNP SNP and with germline
coverage of at least 10. The somatic frequency for that range
was defined as the weighted mean of individual SNV fre-
quencies, weighted by the one minus the probability that
this could be a SNP given the germline coverage. The CN
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was a segment of constant value for the selected region, but
was computed as the mean across all somatic SNVs. To cor-
rect for low purity (percentage of tumor in specimen), we
divided the log2 ratio by the global tumor purity estimated
from all variants. We expected the MMAF m for a deletion
in clone present in a fraction ci of the tumor in a sample
with purity x to be m = x*ci/((2*(1−ci*x)) + 1*x*ci). If all
mutations in that region occurred before deletion events, m
should be given by this formula. If some mutation occurred
after deletion events, m will be reduced by the fraction fi of
the clone for sample i carrying the mutation (Supplemen-
tary Figure S5)
m = x ∗ ci ∗ fi/((2 ∗ (1 − ci ∗ x)) + 1 ∗ x ∗ ci . (1)
With each purity-corrected CNA = cix, we computed a
mean estimator F for the low stage/late stage factor as
F =< fi >= 1n
∑n
i=1 (m− cna)
(
2 ∗ (1 − cna)
cna
)
. (2)
We estimated the minimum and maximum confidence
range using leave-one-out cross validation. In Supplemen-
tary Figure S1, the red line is the data fit, while the blue lines
are the fit from the leave-one-out cross validation data sets.
A one-sidedWilcoxon test of fi-1 is used to estimate the sig-
nificance of the results when F<1.
Kataegis analysis
Mutations were additionally filtered to remove mutations
that are potentially from mapping artifact by removing any
mutations where a 100 bp region surrounding the muta-
tion maps at more than three locations on the genome at
90% identity using Basic Local Alignment Search Tool. The
graph was generated to plots the distance between con-
secutive mutations on a sample. Pink and black lines at
the bottom alternate color between different chromosomes
(even and odd chromosomes), and vertical dotted green
lines highlight chromosome boundaries.
HR-deficient signatures
The signature from (21) was used to create a heatmap. Be-
cause the signature was created on a different platform, we
only selected genes with the top 50% of expression in our
data set and a ratio of standard deviation to median expres-
sion in the top 50%. Gene counts were divided by the to-
tal gene counts of each sample, and the median was sub-
tracted prior to dividing by the standard deviation. Hierar-
chical clustering of the samples was performed in R using
the heatmap function with the Euclidean distance metric.
Results are shown in Supplementary Figure S2.
Structural variant analyses
Structural variants (SVs) were called using CREST 1.0 (22),
SVs where the ends were within 10 bp of each other were
marked as duplicate and only counted once. SVs within 1
Mb of each other were considered clustered.
RESULTS
From 16 low stage HGS ovarian cancer cases treated at the
MayoClinic, we generated an average of 46-fold coverage of
the haploid genomes (tumor and matched germline DNA)
by whole genome sequencing. Approximately 93% of the
exomes and 86% of the genomes were covered by at least
10 reads in both tumor and germline DNA (Supplemen-
tary Table S1). Concordance between sequencing SNVs and
SNP array genotypes was greater than 97% (Supplemen-
tary Table S6). In total, we identified 138 767 somatic sin-
gle nucleotide mutations among 15 low stage HGS carcino-
mas (Table 1) and 1 087 366 somatic single nucleotide muta-
tions in an ultramutated low stage cancer. The ultramutated
stage IC HGS carcinoma was obtained from a patient not
exposed to prior chemotherapy or radiation therapy and
without any previous cancer diagnosis. This ultramutated
carcinoma had a POLE V411L mutation previously impli-
cated in ultramutated endometrial (23,24) and colorectal
carcinomas (25). Excluding this carcinoma, there were a to-
tal of 949 coding or splice-site somatic mutations among
the remaining 15 low stage HGS ovarian carcinomas. From
this point forward, analyses excluded the ultramutated car-
cinoma unless otherwise stated.
Among the 15 low stage HGS cases, there were a greater
number of non-synonymous than synonymous somatic mu-
tations (paired t-test, P<1.1×10−4) (Figure 1A), with a
mean ratio of 2.89; this was also true for the ultramutated
cancer. C to T (C>T) transitions were the most common
mutations (27%) and were enriched relative to the mean
number of mutations per type (P = 7.0×10−8). The least
common mutations were T>G transversions (8%) (Sup-
plementary Table S7), which were rarer than expected by
chance (P = 8.0×10−6). Enrichment of C>T at CpG sites
was different in exonic versus non-exonic regions. Within
the exonic regions, C>T substitutions were significantly
higher at CpG sites than at non-CpG sites (paired t-test, P
= 2.5×10−4) (Figure 1B). High rates of C>T substitutions
at CpG sites were also observed in previous tumor exome
studies (26,27); the deamination of methylated Cs has been
suggested as a possible mechanism of C>T substitutions.
In contrast, in non-exonic regions, C>T substitution rates
at CpG and non-CpG sites were similar (P = 0.19) (Fig-
ure 1C), consistent with global hypomethylation in cancers
(28).
Most chromosomes showed similar mutation rates,
and all showed greater transition than transversion
rates (Figure 2A). Chromosomes 17, 19 and 22 showed
significantly higher genomic (exonic + non-exonic)
transition/transversion ratios compared to the average
(paired t-test, P-values 0.03, 0.048 and 0.007, respec-
tively) (Figure 2B), which may reflect the fact that these
chromosomes have the highest GC content. These chro-
mosomes also had the lowest non-exonic mutation rates
(Figure 2C). Chromosome X had significantly lower
transition/transversion ratios than the genome-wide av-
erage (P = 0.0198) (Figure 2B). The ultramutated cancer
(Patient D) also had more transitions than transversions
(Supplementary Table S7). Genome wide, the mutation
rate was significantly higher in the non-exonic regions
compared to the exome (paired t-test, P = 2.0×10−17)
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/43/14/6945/1098667 by W
ashington U
niversity in St. Louis user on 28 O
ctober 2019
Nucleic Acids Research, 2015, Vol. 43, No. 14 6949
T
ab
le
1
C
ou
nt
of
so
m
at
ic
m
ut
at
io
ns
pe
r
pa
ti
en
t
by
m
ut
at
io
n
ty
pe
SN
V
an
no
ta
ti
on
IN
D
E
L
an
no
ta
ti
on
P
at
ie
nt
3′
F
la
nk
M
is
se
ns
e
5′
U
T
R
N
on
se
ns
e
In
te
rg
en
ic
Sp
lic
e
si
te
Si
le
nt
5′
F
la
nk
D
e
no
vo
st
ar
t
In
F
ra
m
e
3′
U
T
R
In
tr
on
3′
F
la
nk
3′
U
T
R
5′
F
la
nk
F
ra
m
e
sh
if
t
de
l
F
ra
m
e
sh
if
t
in
s
In
te
rg
en
ic
In
tr
on
To
ta
l
pe
r
pa
ti
en
t
A
19
9
25
3
2
43
09
1
13
13
8
1
25
21
71
16
2
10
2
0
26
5
16
1
73
43
B
88
16
1
2
29
65
0
2
75
0
17
13
92
5
0
8
0
0
11
4
48
47
33
C
17
8
26
3
1
41
04
0
9
15
0
0
35
18
92
14
1
14
1
1
26
3
14
6
68
38
D
23
47
4
50
92
21
7
45
3
63
87
44
10
3
19
63
17
98
9
73
53
16
33
83
17
13
85
31
1
11
01
66
37
33
15
6
19
56
9
10
87
36
6
E
30
3
59
8
1
68
55
1
17
21
2
1
45
35
41
13
2
16
0
0
26
3
12
3
11
46
0
F
19
6
25
4
2
42
52
2
14
13
5
2
24
21
04
32
3
12
4
2
37
1
19
6
73
80
G
30
4
61
3
4
66
25
3
23
22
9
1
51
34
47
29
6
20
3
1
32
7
23
5
11
37
2
H
47
4
0
1
12
39
1
5
40
0
8
61
1
4
2
3
1
2
80
62
21
10
I
14
1
18
4
2
35
60
1
12
12
8
0
19
17
78
24
1
17
3
2
29
4
19
0
61
94
J
17
3
29
3
2
42
53
1
13
15
2
2
46
22
70
24
1
11
6
1
34
0
17
9
75
06
K
25
9
24
4
1
44
48
1
15
17
5
0
20
23
38
26
1
21
0
4
28
2
19
8
78
17
L
14
1
23
2
1
35
87
1
9
12
0
0
15
17
68
10
2
7
3
0
17
3
10
9
59
71
M
47
7
86
2
6
98
83
7
39
38
2
1
68
50
30
32
1
26
5
1
61
5
35
0
17
01
1
N
37
1
75
5
6
10
22
7
1
22
32
9
3
62
46
21
52
5
29
3
0
88
6
44
3
17
14
0
O
13
3
21
0
1
38
93
1
11
13
1
0
14
18
03
16
2
10
0
1
18
8
10
5
63
30
P
47
8
97
10
6
11
96
8
2
35
36
6
1
74
59
44
25
2
11
1
1
34
5
19
6
19
56
2
To
ta
l
w
it
ho
ut
P
at
ie
nt
D
34
88
58
9
52
38
82
16
8
23
23
9
27
62
12
52
3
40
71
0
32
2
31
21
5
32
16
48
06
27
41
13
87
67
To
ta
lu
ni
qu
e
co
di
ng
w
it
ho
ut
P
at
ie
nt
D
:
94
9
To
ta
lu
ni
qu
e
no
n-
co
di
ng
w
it
ho
ut
P
at
ie
nt
D
:1
29
12
8
Su
m
m
ar
y
of
m
ut
at
io
ns
by
re
gi
on
an
d
fu
nc
ti
on
al
cl
as
si
fic
at
io
n
ac
co
rd
in
g
to
SN
P
E
F
F.
N
ot
e
th
at
th
e
ca
nc
er
fr
om
P
at
ie
nt
D
ha
d
an
ul
tr
am
ut
at
ed
ph
en
ot
yp
e.
Figure 1. Somatic mutation rates in early stage ovarian cancer genomes.
(A) Rate of synonymous and non-synonymous mutations in 15 early stage
ovarian cancer genomes. (B and C) Mutation rate for selected types of
mutation (indicating nucleotide before mutated nucleotide, nucleotide to
mutate and possible product of mutation) for each cancer, divided by the
number of mutational contexts for each mutation type, in order to detect
possible biases for mutational processes (e.g. CpG->(G/A) has two con-
texts) in exonic regions (B) and non-exonic regions (C). Note that C>T so-
matic substitutions are significantly higher at CpG sites than at non-CpG
sites in coding regions (B) but not in non-coding regions (C). A>mut is the
mutation rate of A to any other substitutions.
(Figure 2D), suggesting some selection against mutations
in exonic regions.
Recent studies have uncovered the presence of hyper-
mutated regions, termed kataegis, in some cancer genomes
(29). Therefore, we investigated evidence for kataegis among
the 16 low stage HGS ovarian carcinomas. We found ev-
idence of a potential kataegis event in chromosome 19 in
Patient I, a stage I ovarian cancer (Figure 3A). In addition,
we found a novel chromosome-wide hypermutational event
with enriched T>C substitutions in chromosome 6 in the
cancer from Patient C with stage IB disease (Figure 3B).
This observation is novel because previous kataegis events
were associatedwith either C>TorC>Gsubstitutions (29).
Excluding the ultramutated cancer, the coding sequences
of 38 genes were mutated in more than one of the 15 low
stageHGSovarian carcinomas andwere above the expected
background mutation rates corrected for gene size and spe-
cificmutation rate (Table 2).Manual curation ofmapped se-
quences using IGV (30,31) revealed that the TP53 gene was
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Figure 2. Somatic mutation patterns in early stage ovarian cancer genomes. (A) Total transition and transversion rates (across 15 carcinomas, divided by
15 to get per patient rates) for all regions within each chromosome and mean mutation rates in coding and non-coding regions within each chromosome.
(B) Fraction of transition (%Ts), transversion (%Tv) and the ratio of Ts/Tv for each chromosome. (C) Total transition and transversion rates within coding
and non-coding regions of each chromosome. (D) Mutation rates within coding (exonic), non-coding (non-exonic) regions for each cancer on the x-axis.
Median is indicated by red dotted line. Note that mutation rates in non-coding regions are consistently higher than mutation rates within coding regions.
mutated in all but one of the Mayo Clinic low stage HGS
ovarian carcinomas (Table 3) and at high mutant frequency
when results in these carcinomas were combined with the 28
low stage HGS carcinomas of TCGA (Supplementary Ta-
ble S8). A high frequency of mutations was found through-
out the TP53 coding regions as well as at known hotspots,
consistent with the mutation profiles of tumor suppressor
genes (26,32). Consistent with the presence of TP53 muta-
tions, high levels of p53 staining were observed in all but
two cases analyzed (Table 3 and Supplementary Figure S3).
These data are consistent with results ofTP53 studies in late
stage (6,33) and low stage HGS ovarian carcinomas (34).
Combined with the Mayo Clinic data, results collectively
support the hypothesis thatmutations inTP53 represent the
earliest documented genetic lesions in HGS ovarian cancer
(34). For a subset of 14 patients with RNA sequence data
(Table 3), the mutant allele was observed at a higher fre-
quency than the wild type allele, either through deletion of
the wild type allele or through epigenetic silencing of the
other allele by mechanisms that were not further character-
ized here. The cancer from Patient H is the only with no
mutation in TP53; this cancer, however, had a mutation in
theCHEK2 (p.V246L) gene, although the functional signif-
icance of this somatic mutation is not known .
In addition to TP53, there were additional alterations in
genes frequently mutated in late stage HGS (Table 4). In
particular, our low stage cases contained potentially dele-
terious somatic variants of unknown significance (VUSs)
in BRCA2 (Patient F: P2612S and Patient M: K2017I)
and CSMD3 (Patient K: P1653Q). Moreover, one case (Pa-
tient P) had a germline frameshift mutation in exon 13
of BRCA2 mutation along with somatic loss of the non-
mutated allele in the cancer. Patients C, D, F and G also
have germline VUSs in BRCA2. For Patients F andM, with
somatic BRCA2 mutations, the mutant BRCA2 allele was
homozygous (Table 4) as often occurs in functional muta-
tion of tumor suppressor genes; however, both variants are
VUSs. In addition, Patient N acquired a homozygous dele-
terious somatic mutation in BRCA1 (Frameshift in exon
17, rs80357572) (36 out of 43 reads carried mutation), and
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Table 2. Significantly mutated genes in early stage HGS ovarian cancer from 15 Mayo Clinic patients
Gene Indels SNVs Covered bps Mutations per Mb P-value
TP53 4 6 61 321 163.08 <10E−10
TPSAB1 0 3 7 483 400.91 0.0000381
FOXD4L1 0 2 16 900 118.34 0.017
XIRP2 1 2 196 902 15.24 0.017
VEGFC 0 2 29 078 68.78 0.047
FAM55D 0 2 37 974 52.67 0.054
ASCC3 0 3 194 324 15.44 0.035
GPR179 0 3 130 368 23.01 0.067
AMIGO2 0 2 55 035 36.34 0.073
NUP210L 0 2 130 499 15.33 0.084
CDSN 0 2 39 312 50.88 0.087
P2RY13 0 2 44 273 45.17 0.115
SLC5A7 0 2 82 795 24.16 0.127
CHRM3 0 2 39 835 50.21 0.136
DYNC1I1 0 2 70 529 28.36 0.163
ANUBL1 0 2 69 303 28.86 0.173
LRRC2 0 2 84 448 23.68 0.210
CACNA2D1 0 2 119 338 16.76 0.192
BRCA2 0 2 198 810 10.06 0.296
UNC5D 0 2 133 980 14.93 0.330
MUC16 0 3 796 308 3.77 0.210
CC2D2A 0 2 145 597 13.74 0.350
SHROOM2 0 2 114 872 17.41 0.355
MUC2 0 2 155 671 12.85 0.331
MYO16 0 2 165 213 12.11 0.357
MUC5B 0 2 208 010 9.61 0.353
PKHD1L1 0 2 288 344 6.94 0.360
PIK3C2B 0 2 164 801 12.14 0.440
MLL3 0 2 313 318 6.38 0.352
IGFN1 0 2 202 275 9.89 0.554
DNAH7 0 2 288 837 6.92 0.520
Significantly mutated genes using genome music in Mayo Clinic samples. Only genes with at least two mutations are shown; Indels, number of
insertion/deletion variants in the region/gene; SNVs, number of single nucleotide variants (SNV) in the region/gene; Total mutations, total number
of SNVs and Indels; Covered bps, gene size in base pairs; Mutations per Mb, mutations per Megabase; P-value is from Fisher’s combined P-value test;
additional mutations were found in the following genes which are members of gene families or highly polymorphic HLA-DRB1, HLA-DQA1, OR2A14,
MUC4, KRTAP4–7, OR4A47 and TTN.
the ultramutated carcinoma (Patient D) acquired a VUS in
BRCA1 (T231N). Patient B had a germline VUS in BRCA1
(E1167K, rs80356923), but with predicted deleterious ef-
fects.
Results described by the TCGA suggest that many HGS
ovarian carcinomas have both extensive changes in CN and
defects in the homologous recombination (HR) pathway
(6). Subsequent studies have suggested that LOH changes
correlate with HR defects (35). Therefore, we summarized
CN and LOH changes and examined evidence of defects in
HR. The number of long LOH regions (>15Mb), called the
homologous recombination deficiency score (HRD score),
in cancer genomes has been shown to correlate with the de-
ficiencies in HR (35). We determined this HRD score us-
ing theWaveCNV package to estimate LOH and also deter-
mined anHRD-like score (counting CN decrease instead of
LOH). High HRD scores (>15) were found in 10 out of the
16 low stage HGS carcinomas. The six carcinomas with low
HRD scores were patients with high predicted ploidy and
the ultramutated cancer for Patient D (Table 4 and Supple-
mentary Table S5).
The majority of carcinomas with high HRD scores
(HRD score ≥ 15) contained alterations in HR genes, sug-
gesting potential defects in HR pathway (Table 4). These
defects included somatic homozygous frameshift muta-
tion in BRCA1 (Patient N), somatic homozygous muta-
tions in BRCA2 (Patients F and M), known delerious
(36 ) RAD51C mutation (Patient L), CN loss associated
with BRCA1, BRCA2 and RAD51D (Patient J), and CN
loss associated with BRCA1, RAD51C and RAD51D (Pa-
tient I). Patient P had a germline frameshift mutation in
BRCA2 that became homozygous in the carcinoma, sug-
gestive of a potentially deleterious mutation. Interestingly,
this carcinoma has a low HRD score. In carcinomas from
Patients A, G and M with high HRD scores, BRCA1
and/or BRCA2 mRNA were markedly downregulated by
RNA-sequencing analysis (Table 4) and qRT-PCR (data
not shown). Thus, it appears that decreased expression, like
deleterious mutations, might contribute to genomic insta-
bility, as manifested by a highHRD score, in these low stage
HGS ovarian carcinomas.
Carcinomas from three patients (Patients E, O and P), in-
cluding a patient with homozygous frameshift mutation in
BRCA2 (Patient P), had relatively low HRD scores (< 10)
and low genome-wide LOH burden (<0.10). The estimated
CN in these carcinomas was comparable to tetraploidy
(WaveCNV > 3.5, Supplementary Table S5).
To explore additional evidence for HR deficiency, we
conducted hierarchical clustering of RNAseq data using
a signature of genes differentially expressed between HR-
deficient and HR-competent cell lines (21). Carcinomas
with confirmed deleteriousmutations inHRgenes clustered
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Figure 3. Kataegis events in early stage ovarian cancer genomes. (A) Pa-
tient I. (B) Patient C. The ‘rainfall’ plots represent total mutational events
from individual carcinomas, and each dot represents a single somatic mu-
tation plotted on the horizontal axis corresponding to its order in the hu-
man genome. Regions of interest with kataegis events are shown in purple
boxes.
closely with those with LOH in multiple HR genes (Sup-
plementary Figure S2). For example, carcinomas from Pa-
tients C andGappear to cluster together and both have high
HRD score, low BRCA1 expression and BRCA1 LOH. In
addition, PatientGhas a germlineBRCA2P451QVUS that
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Figure 4. Correlation between PRIM2 copy number and expression. Re-
sults show that somatic deletions in that region correlate with reduce ex-
pression of the PRIM2 gene in Mayo Clinic and TCGA early stage HGS
ovarian carcinomas; Spearman correlation coefficient and P-value shown.
became homozygous in the carcinoma. Carcinomas from
PatientsM andN cluster together and both have highHRD
score and homozygous somatic mutations in BRCA2 and
BRCA1, respectively. Carcinomas from Patients A, B, O, E
and K form another cluster with those from Patients A and
B having high HRD score, the carcinoma from Patient K
is just below the cutoff (HRD score < 15) and those from
Patients O and E have low HRD score but have high ploidy.
Carcinomas from Patients P, I and L form another group
with mixed HRD score. This later group consists of Patient
P with low HRD score who has a homozygous frameshift
mutation in BRCA2 and Patient I with high HRD score.
Using CN data from microarrays, we identified three re-
current regions of CNA where the frequency of alteration
appeared to differ between low and late stage HGS ovarian
carcinomas (TERT, SKP2 and PRIM2). However, only the
PRIM2 region showed a consistent CN difference between
low stage and late stage cases (Supplementary Figure S4)
when aCGH CN data from TCGA was used as a technical
validation (P= 1.1 × 10−11). PRIM2 also exhibited signifi-
cant changes in mRNA levels with a significant expression–
CN correlation (Figure 4).
The MMAF versus purity-corrected CN frequency can
be used to infer the sequence of genetic alterations in the
evolution of cancer (Supplementary Figure S5). In Supple-
mentary Figure S1, we provide the MMAF versus purity-
corrected CN in 15 patients. We computed the factor F
(see Materials and Methods section) for three key genes
using carcinomas with deletions with log2 ratio ≤ −0.3
and one or more somatic mutation. In Supplementary Fig-
ure S5, an F factor of 1 indicates that mutations arose be-
fore the CN event. Considering any somatic mutation, we
found that BRCA2 somatic mutations (chr 13) occurred be-
fore CN events with F = 0.98 [0.85–1.16] (Pwilcox = 0.125),
based on four carcinomas. However, TP53 (chr 17), with F
= 0.62 [0.55–0.83] (Pwilcox = 0.01) from seven carcinomas
and BRCA1 (chr 17), with F = 0.63 [0.61–0.68] (Pwilcox =
0.007) from eight carcinomas, did not show the same pat-
tern. This suggests that the accumulation of somatic mu-
tations in BRCA2 occurred prior to the deletion of chro-
mosome 13 but that multiple somatic mutations occurred
on chromosome 17 (TP53 and BRCA1) after the CN dele-
tion. However, in Supplementary Figure S1D, we limited to
deleterious-only TP53 mutations. In this case, we found F
= 1.10 (1.03–1.11) with seven carcinomas, suggesting that
the deleterious TP53 mutations predate the deletion of the
other functional allele. Overall, this analysis indicates that
a heterozygous somatic mutation in TP53 is an early event
which, in some samples, is followed by a chromosome 17
deletion resulting in TP53 inactivation at a relatively early
point in the progression of the carcinoma. In contrast, chro-
mosome 13 deletions are a relatively later event in the evo-
lution of HGS ovarian cancer in this study.
Supplementary Figure S6 shows the genome-wide distri-
bution of LOH for all samples, with the relative number
of samples with an LOH event plotted in blue at the bot-
tom of the figure. We observed that LOH was most com-
mon in chromosome 17 (14 samples, 54–70M), followed by
4q31–35 (11 samples), 22q12 (12 samples), 9q33 (11 sam-
ples), 8p23 (10 samples), 18q (10 samples), X (10 samples),
1p (nine samples) and 13p (nine samples). Supplementary
Figure S7 shows a clustered genome-wide LOH heatmap
and Supplementary Figure S8 shows the LOH heatmaps
for the chromosomes with the greatest LOH. Despite the
widespread LOH in most samples, carcinomas from Pa-
tients E, O and P, which had high mean ploidy, had low
LOH as indicated above.
Finally, to identify somatic structural variation (SVs)
such as large INDELs and interchromosomal transloca-
tions, we applied the CREST bioinformatics tool and char-
acterized somatic SVs uncovered in these samples. Results
shown in Supplementary Table S9 indicates heterogeneity in
SV burden in these tumors. Interestingly, the ultramutated
carcinoma from Patient D has no detectable SV in addition
to little CNV. Genes affected by recurrent translocation in
at least two samples are shown in Supplementary Table S10.
DAVID Bioinformatics Analysis (37) of functional annota-
tion of genes affected by recurrent SVs in these samples in-
dicate cell projection, morphogenesis and GTPase regula-
tor activities as biological functions affected by these genes
(Supplementary Table S11). It is striking that 43% of the
SV events (Supplementary Table S12) cluster in groups of
SVs (separated by 1 MB or less). The paucity of Kataegis
events but presence of clustered SVs in these samples raises
the possibility that these might be a preferential outcome of
showers of DNA damage in OCs with repair defects.
DISCUSSION
Using a rare set of low stage HGS ovarian carcinomas from
theMayo Clinic, we report the first whole genome sequenc-
ing in ovarian cancer and identify early mutational events in
this disease. Integrated analysis of whole genome sequences,
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RNA sequences and CN changes produced five major find-
ings: (i) frequent mutations and LOH in TP53, (2) PRIM2
loss as a frequent genetic alteration, (iii) frequent HR de-
fects and genome-wide CNA ,(iv) clustering of structural
variants in genome, and (v) polyploidy in certain low stage
HGS ovarian cancers, .
TP53 mutations and LOH in low stage HGS ovarian cancer
Our analysis indicates that TP53 is the most frequently mu-
tated gene in low stage HGS ovarian cancer. This observa-
tion, taken together with previous studies indicating that
TP53 mutations are ubiquitous in late stage HGS ovar-
ian cancer (6,33), highlights TP53mutations as the pathog-
nomonic feature ofHGS ovarian cancer. As this patient col-
lection consisted of low stage HGS carcinomas, this find-
ing lends further support to prior studies of early/low stage
HGS, which showed somatic TP53 mutations in serous
tubal intraepithelial carcinomas fromwomenwith germline
mutations in BRCA1 or BRCA2 (38). Our results also indi-
cate that deleterious TP53 mutations precede CN deletion
events that eliminated the wild type copy of TP53. Collec-
tively, these results suggest that the most frequent sequence
of events leading to tumorigenesis in HGS ovarian cancer
is an early somatic mutation in TP53 followed by genome-
wide LOH that often includes CN loss in chromosomes 13
or 17.
Detailed analysis of TP53 mutations in our study led to
three additional observations. First, we identified loss of the
wild type copy via deletion or LOH in 10 out of 16 low stage
HGS carcinomas with mutant TP53. Second, in the carci-
nomas without allelic loss of wild type TP53, expression
analysis showed inactivation of the transcriptional activity
of the wild type copy in our RNA sequence data for four
more carcinomas. Third, one cancer without any TP53mu-
tation (Patient H) had the smallest number of deleterious
somatic mutations (four missense, one nonsense and one
splice-site mutations), yet had a relatively high HRD score.
Interestingly, this carcinoma also had no mutations in the
high frequency driver genes found by TCGA, namely,NF1,
CDK12, FAT3, GAGRA6, BRCA1 and RB1. It did, how-
ever, have a somatic CHEK2 mutation, which might well
account for the genomic instability as manifested by the
relatively high HRD score. Interestingly, Patient H is also
the only patient with stage I ovarian carcinoma who experi-
enced recurrence and died from the disease (Supplementary
Tables S1 and Table S13).
In this series of low stage HGS ovarian carcinomas, we
observed four TP53 mutations (R273C, R248W, R248Q
and R175H) that were previously described as ‘neomor-
phic’ (gain of function, GOF) changes (39). The frequency
of neomorphic mutations in the Mayo Clinic carcinomas
was similar to that reported in the TCGA set of primar-
ily late stage carcinomas (P-value 1.0, t-test). Some of
these neomorphic mutations have been shown to produce
metastatic tumors in mouse model systems. For example,
R172H (equivalent to R175H in human) mutant mice pro-
duce highly metastatic tumors (40,41). It is therefore inter-
esting that a neomorphic TP53 mutation, R175H, is found
in early stage ovarian cancer (Patient C) with stage IB at di-
agnosis. It is possible that incidental finding of some of these
early stage carcinomas may have limited the metastatic po-
tential. In addition, the metastatic behavior of R172H mu-
tant in mice is also host- and dose-dependent (40,41), and
host factors may have limited the metastatic potential of
R175H in this particular case of HGS ovarian carcinoma.
Consistent with the role of GOF TP53 mutants in promot-
ing metastatic potential, Kang et al. observed that patients
with GOF TP53mutations in the TCGA cohort were more
likely to develop distantmetastasis (42). However, no signif-
icant association between GOF TP53 mutations and clini-
cal outcome was observed (42). These results are also con-
sistent with prior studies by Ahmed et al., who also found
no significant association between two types of TP53muta-
tions (missense versus non-missense) and clinical outcome
(33).
The other three patients with putative neomorphic TP53
mutations were diagnosed with stage II carcinomas. Two
of them (Patients K and O) had low HRD scores and
no defects in HR genes. Since HR deficiency is associ-
ated with better response to platinum-based chemotherapy
and PARP inhibitors (6,43–44), it would be important to
investigate the extent to which some of the neomorphic
TP53 mutations are associated with HR proficiency and
whether these mutants are associated with poor response
to platinum-based chemotherapy or PARP inhibitors.
PRIM2 loss as a frequent alteration in early/low stage HGS
ovarian cancer
Our results showed that the PRIM2 gene was more fre-
quently deleted in early stage than in late stageHGSovarian
cancer.PRIM2 encodesDNAprimase polypeptide 2, which
is involved in DNA replication and synthesizes Okazaki
fragments to seed DNA replication starting points. It is
possible that lower levels of this enzyme facilitate struc-
tural rearrangements by disruption of DNA replication.
Studies in the Saccharomyces cerevisiae model system indi-
cate that defects in lagging-strand replication are repaired
by a RAD51-dependent mechanism (45). Therefore, both
PRIM2 loss and RAD51 downregulation in HGS cancer
may result in utilization of the error-prone repair pathway
(e.g. non-homologous end joining) and may contribute to
the extensive rearrangements found in HGS ovarian can-
cer. Interestingly, both PRIM2 loss and CHEK2 mutation
are observed in the cancer fromPatientHwithout anyTP53
mutations. The CNAs observed this cancer are comparable
to other early stage HGS ovarian carcinomas with TP53
mutations and HR defects, suggesting the possibility that
PRIM2 and CHEK2 loss in Patient H may contribute to
comparable levels of structural alterations.
HR defects and genome-wide LOH
The pattern of LOH found in early stage HGS ovarian car-
cinomas is consistent with the pattern previously reported
in late stage disease (19). Wang et al. reported chromosome
17 and 13 as the two chromosomes most frequently exhibit-
ing large-scale LOH. While our results replicate the earlier
findings for chromosome 17 (LOH in 14 samples), chromo-
some 13 LOH occurred in only nine samples, and other re-
gions were more frequently subject to LOH [22q12 (12 sam-
ples), 4q31–35 (11 samples), 9q33 (11 samples), 8p23 (10
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samples), 18q (10 samples) and X (10 samples)]. This lower
frequency of chromosome 13 LOH compared to chromo-
some 17 reinforces our thesis that chromosome 13 LOH
may be a later event. Although this conclusion is limited
by small sample size, this is consistent with our joint anal-
ysis of mutations and deletions on chromosome 13, which
showed deletions to be late events.
SVs and clustered damage
In contrast to a number of cancers, where clusters of point
mutations called Kataegis events are observed, few such
events were observed in the low stage HGS ovarian can-
cers examined here. On the other hand, many of the SVs
detected in the low stage ovarian cancer samples occurred
in clusters. These results suggest that DNA damage might
have occurred in clusters in these tumors but, perhaps be-
cause of differences in repair capacities or anomalous func-
tion of the topo-isomerase genes, led to clusters of double-
strand breaks and subsequent SVs in early ovarian cancer
with lower rates of Kataegis events than observed in other
cancers (46).
Polyploidy in carcinomas with minimal LOH
TheMayoClinic carcinomaswith highHRD scores showed
LOHalteration, consistent withWang’s ‘ClusterHiA’ (High
LOH) carcinomas with HR defects and good response to
platinum therapy (19). The Mayo Clinic carcinomas with
low levels of LOH had low HRD scores and were similar to
Wang’s cluster Lo carcinomas, which were less responsive
to platinum therapies (19), presumably due to a functional
HR pathway. Our observations also indicate that carcino-
mas with low LOH are associated with polyploidy, which
has also been implicated in cisplatin resistance (47) and as-
sociated with worse prognosis (48).
We are the first to show the co-existence of polyploidy
and low genomic LOH in HGS ovarian carcinoma. Co-
existence of polyploidy and functional HR in these sam-
ples would be consistent with prior studies in yeast indicat-
ing the synthetic lethality of tetraploidy and HR defects in
yeast (49). However, there is other evidence that tetraploid
tumors can have defective HR (via BRCA1mutation) at the
same rate as diploid tumors (50). It is also possible that the
tetraploid tumors are not able to display a high HRD score
despite the presence of a HR defect.
Previous studies in mice identified a possible mechanism
of ovarian epithelial tumorigenesis via a transition to a
tetraploid state (51) followed by aneuploidy changes as long
as TP53mutations were present. Carcinomas from Patients
O, P and E may be in the earliest stages of this trans-
formation and have not yet undergone transition toward
the diploid state with a high frequency of LOH despite
strong evidence of HR inactivation in Patient P (homozy-
gous frameshift mutation of BRCA2). Thus, some of those
tetraploid tumors may still have a defective HR pathway
despite exhibiting a low HRD score. Nevertheless many
tetraploid tumors may still be HR competent to explain
the higher recurrence rate of low LOH tumors in (19). This
hypothesis is also supported by the clustering of carcino-
mas from Patients O, P and E with other samples with high
HRD scores based on the gene expression signature previ-
ously described (21).
Lastly, we found one ultramutated carcinoma (Patient
D), which initially appeared completely different from other
patients. This cancer had POLE V411L mutation that was
characterized as one of the hotspot mutations in ultramu-
tated endometrial and colorectal carcinomas (25,52). This
patient had minimal levels of SV, CNV and LOH and thus
the same pattern as seen in other carcinomas with high rate
of somatic SNVs (53). For this cancer, it is likely thatPOLE
mutation contributes to an ultramutated phenotype with
low levels of structural alterations.
CONCLUSIONS
Although our sample size is limited due to the rarity of low
stage HGS ovarian carcinomas, the overall genomic land-
scape of these carcinomas is remarkably similar to late stage
HGS ovarian carcinomas in mutation spectrum, burden
and structural rearrangement. These results, which are con-
sistent with the earlier observation by Kobel et al. that early
and late stage HGS carcinomas are indistinguishable based
on immunohistochemical analysis 21 biomarkers (54), ex-
tend these findings to the whole-genome level.
While TP53 mutation is a key early event, we have not
identified an event that would lead to a high rate of somatic
mutations to initially inactivate TP53. Additional studies
evaluating candidatemechanisms, such asAPOBEC3B (46)
are needed to understand initial carcinogenic events that
lead to inactivation of TP53. Our data, which show that
mutations in TP53may be driver events in ovarian carcino-
genesis, provide additional impetus for efforts to restore the
function of TP53 or exploit its deficit in patients with HGS
ovarian cancer. The present results also indicate that chro-
mosome 13 events (CN changes or LOH) are later than
chromosome 17 events. We have also identified one early
stage HGS ovarian cancer with an ultramutated phenotype,
but LOH analysis has revealed that this ultramutated phe-
notype is superimposed on a background of low-levels CN
and LOH events consistent with many of the other low
stage, HGS ovarian carcinomas, indicating that this is also
a late event. In addition, we identified several carcinomas
with low LOH and high estimated ploidy which is consis-
tent with the model in which someHGS ovarian cancers are
initially tetraploid and become nearly diploid due to LOH.
Despite heterogeneity in somatic sequence variations,
CNAs and structural variations, none of these somatic
genotypes appears to be associated with clinical outcome.
Only stage appears to be strongly linked to patient survival,
as six of eight patients with stage I HGS ovarian carcino-
mas are still alive (median follow-up 101 months), whereas
only two of eight with stage 2 disease are still alive (median
follow-up 79 months). Collectively, these observations pro-
vide new insight into the biology and likely pathogenesis of
early stage HGS ovarian cancer.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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